Healio

EPO biosimilar shows efficacy similar to epoetin alfa

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results of a 24-week trial that compared ...
Cure Today

FDA Approves Biosimilar to Treat Chemotherapy-Related Anemia

The Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx), a biosimilar of Epogen/Procrit (epoetin alfa), to treat anemia caused by a number of factors – including undergoing ...
Healio

FDA approves Retacrit, an Epogen/Procrit biosimilar, for treatment of anemia

Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Monthly Prescribing Reference

FDA Approves Epoetin Alfa Biosimilar Retacrit

FDA LOGO BLUE The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data ...
Monthly Prescribing Reference

ESA Biosimilar Effective for Anemia in Hemodialysis Patients

Credit: Getty Images. Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa. For hemodialysis (HD) patients with ...
PharmTech

FDA Approves Pfizer’s Epoetin Alfa Biosimilar

The agency has approved Retacrit (epoetin alfa-epbx) by Pfizer’s Hospira, which is a biosimilar to Amgen’s anemia drug, Epogen/Procrit (epoetin alfa). On May 15, 2018, FDA announced that it has ...
Reuters

Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA

* PFIZER INC - RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT * PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA ...